Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMA: CE/BZA for Mood in Menopause
NCT04478305Phase 1Recruiting
- Sponsor
- St. Joseph's Healthcare Hamilton
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bazedoxifene + conjugated estrogens in major depressive disorder (MDD) and anxiety disorder, sponsored by St. Joseph's Healthcare Hamilton. Primary endpoints: Depressive symptoms at 16 weeks and Anxiety symptoms at 16 weeks. Started Jul 2024; status: recruiting.
02
Drugs
bazedoxifene + conjugated estrogens
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT04478305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478305.